


Das MK, Lumb V, Mittra P, Singh SS, Dash AP, Sharma YD (2010). High chloroquine treatment failure rates and pre-dominance of mutant genotypes associated with


References


NMEP, (1985). In-depth evaluation report of the modified plan of operation under National Malaria Eradication Programme of India (Delhi: National Malaria Eradication Programme)


Sutar SKD, Dhangadamajhi G, Kar SK, Ranjit M (2013). Molecular monitoring of anti-
malarial drug resistance among *Plasmodium falciparum* field isolates from Odisha,

Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, Fukuda MM,
Hien TT, Mayxay M, Noedl H, Nosten F, KyawMP, Nhien NT, ImwongM, Bethell D,
Se Y, Lon C, Tyner SD, Saunders DL, Arrey F, Mercereau-Puijalon O, Menard D,
Newton PN, Khantavong M, Hongvanthong B, Starzengruber P, Fuehrer HP,
CS, Bailey J, Tan JC, Ferdig MT, Clark TG, Miotto O, Maclnness B, Kwiatkowski DP,
670–9.

evolutionary genetics analysis using maximum likelihood, evolutionary distance, and

Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, Kokwaro G, Aseffa A,
Engers H (2008). Chloroquine-resistant *Plasmodium vivax* malaria in Debre Zeit,

Than N, Manoj D, Michael R, Alan CF (2003). Analysis of *Pfcr*, *pfmdr-1*, *dhfr* and *dhps*
mutation and drug sensitivities in *Plasmodium falciparum* isolates from patients in
356.

synthase are responsible for sulfone and sulfonamide resistance in *Plasmodium

Valecha N, Joshi H, Mallick PK, Sharma SK, Kumar A, Tyagi PK, Shahi B, Das MK,
Nagpal BN, Dash AP (2009a). Low efficacy of chloroquine: time to switch over to
artemisinin-based combination therapy for falciparum malaria in India. *Acta Trop.* 111:

Valecha N, Srivastava P, Mohanty SS, Mittra P, Sharma SK, Tyagi PK, Pradhan K, Dev V,

Van Tyne D, Park DJ, Schaffner SF, Neafsey DE, Angelino E, Cortese JF, Barnes KG,
Rosen DM, Lukens AK, Daniels RF, Milner DA Jr, Johnson CA, Shlyakhter I,
Grossman SR, Becker JS, Yamins D, Karlsson EK, Ndiaye D, Sarr O, Mboup S, Happi
Wirth DF, Volkman SK, Sabeti PC (2011). Identification and functional validation of
the novel anti-malarial resistance locus PF10_0355 in *Plasmodium falciparum*. *PLoS
Genet.* 7(4): e1001383.


APPENDIX
Preparation of Reagents

10x TBE Buffer (stock solution) – 1L

108gms Trizma base
54gms Boric Acid
40ml 0.5M EDTA ph 8.0

All the contents were dissolved in 1L of Millipore nuclease free water and autoclaved.

0.5M EDTA ph 8.0 (1L)

186.1 gm EDTA
20gm NaOH pellets

EDTA was dissolved in 800ml of Millipore nuclease free water and ph was adjusted to 8.0 using NaOH. Final volume was made upto 1 liter and was autoclaved.

0.5x TBE buffer (working solution) – 1L

50ml 10x TBE buffer
950ml Millipore nuclease free water

2% Agarose Gel (100ml)

2gm agarose was dissolved in 100ml 0.5x TBE buffer and agarose solution was melted and kept aside to cool. When it was slightly warm 3μl of ethidium bromide (1mg/ml) was added. Mixed well and gel was casted.
Agarose Gel Loading Dye (100ml)

30ml glycerol
70ml distilled
0.25gm bromophenol blue
All the contents were mixed and stored at 4°C.

Ethidum Bromide (1mg/ml)

10mg Ethidium Bromide

10mg of ethidium bromide was dissolved in 10ml of Millipore nuclease free water. Stored at 4°C.
LIST OF PUBLICATIONS
Publications from thesis:


Other publications as a co-author:


